Loomis Sayles & CO L P Xenon Pharmaceuticals Inc. Transaction History
Loomis Sayles & CO L P
- $79.2 Billion
- Q4 2024
A detailed history of Loomis Sayles & CO L P transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Loomis Sayles & CO L P holds 687,145 shares of XENE stock, worth $23.5 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
687,145
Previous 707,222
2.84%
Holding current value
$23.5 Million
Previous $27.8 Million
3.26%
% of portfolio
0.03%
Previous 0.04%
Shares
9 transactions
Others Institutions Holding XENE
# of Institutions
219Shares Held
66.7MCall Options Held
109KPut Options Held
2.1K-
Avoro Capital Advisors LLC New York, NY5.67MShares$194 Million3.24% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.52MShares$155 Million1.73% of portfolio
-
Braidwell LP Stamford, CT2.91MShares$99.8 Million6.4% of portfolio
-
Janus Henderson Group PLC London, X02.87MShares$98.2 Million0.06% of portfolio
-
Commodore Capital LP New York, NY2.74MShares$93.9 Million10.76% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.13B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...